1,099 results on '"Tetzlaff, Michael T."'
Search Results
152. Cutaneous metastasis from anaplastic thyroid carcinoma exhibiting exclusively a spindle cell morphology. A case report and review of literature
153. Role of Radiotherapy in Aggressive Digital Papillary Adenocarcinoma
154. Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma
155. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
156. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
157. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
158. Distinct Pathways in the Pathogenesis of Sebaceous Carcinomas Implicated by Differentially Expressed MicroRNAs
159. Middle cerebral artery territory infarct due to Cryptococcus infectionstitle: ??An uncommon indication for cerebrospinal fluid analysis in stroke patients
160. miR-200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment
161. Identification of Geographic Clustering and Regions Spared by Cutaneous T-Cell Lymphoma in Texas Using 2 Distinct Cancer Registries
162. Identification of an Isoform of the Estrogen Receptor Messenger RNA Lacking Exon Four and Present in the Brain
163. Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms
164. Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network
165. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
166. Abstract LB208: Obesity is associated with lower tumor oxidative phosphorylation (OXPhos) in metastatic melanoma (MM)
167. Abstract 2844: The role of oxidative phosphorylation (OXPHOS) in melanoma brain metastasis (MBM) formation and growth
168. Prognostic significance of acral lentiginous histologic type in T1 melanoma
169. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.
170. Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network.
171. Without Missing a Beat: Absence of Cilia Informs the Diagnosis of Histopathologically Challenging Spitzoid Melanocytic Neoplasms
172. Detection of mitotic figures and G2+ tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma
173. Pigmented extramammary Paget disease of the thigh mimicking a melanocytic tumor: report of a case and review of the literature
174. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma
175. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions
176. The differential diagnosis of CD8-positive (“type D”) lymphomatoid papulosis†
177. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1
178. Dermatopathology in the Molecular Age
179. Dermatopathology
180. Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.
181. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens
182. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
183. Differential Expression of miRNAs in Papillary Thyroid Carcinoma Compared to Multinodular Goiter Using Formalin Fixed Paraffin Embedded Tissues
184. B cells and tertiary lymphoid structures promote immunotherapy response.
185. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
186. Prognostic significance of acral lentiginous histologic type in T1 melanoma
187. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
188. Discordance in Diagnosis of Melanocytic Lesions and Its Impact on Clinical Management
189. iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation
190. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
191. Perianal condylomata lata mimicking carcinoma
192. Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop
193. Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response
194. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
195. Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases
196. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma
197. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein
198. Superficial Neurocristic EWSR1::FLI1 Fusion Tumor: A Distinctive, Clinically Indolent, S100 Protein/SOX10-Positive Neoplasm.
199. Neoadjuvant relatlimab and nivolumab in resectable melanoma
200. Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.